Clinical Trial Details
— Status: Active, not recruiting
Administrative data
NCT number |
NCT05091437 |
Other study ID # |
D133FR00176 |
Secondary ID |
|
Status |
Active, not recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
December 30, 2021 |
Est. completion date |
June 30, 2025 |
Study information
Verified date |
June 2024 |
Source |
AstraZeneca |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Early diagnosis of LC in the asymptomatic stage through intentional screening programs and/or
incidental pulmonary nodule identification and follow-up are known to improve outcomes
significantly. There are large gaps in the screening and early detection of LC, especially in
LMIC - driven by multifactorial aspects, including a variety of socioeconomic and
infrastructural factors, mainly due to limitations in the required network of specialized
human resources and technical capacity. Identifying LC at an early stage allows for treatment
that is more likely to be curative, thereby improving survival.
The present study aims to characterize the lung nodule journey in different hospitals/clinics
across Latin America, describing the use of health resources, time to diagnosis, stage at
diagnosis, and time to treatment depending on the source of nodule identification in two
different cohorts (retrospective and prospective).
Description:
This non-interventional observational study will capture data (retrospective and prospective
cohorts) from around 20 to 25 hospitals/clinics to report lung nodules (patients' journey) in
Latin America.
Objectives and Hypotheses:
Primary objective
• To describe the lung nodule patient journey from the time of nodule identification through
its final diagnosis, staging, and treatment decision.
Note: Lung nodules identified from different settings would be nodules identified
incidentally and in lung cancer screening programs.
Secondary objective(s)
- To determine the medical specialties involved in the lung nodule study journey.
- To describe a medical specialist who first identifies the lung nodule (referral
patterns).
- To estimate the proportion of benign and malignant nodules.
- To understand health care resource utilization from nodule detection to final diagnosis
and management.
- Time from nodule identification until a final diagnosis and treatment decision.
- Treatment decision and specialties involved in the decision.
Study Population:
Adult ≥ 35 years of age with solid or subsolid (part solid, pure ground glass) lung nodules
identified in different settings, including nodules identified incidentally and nodules
identified in lung cancer screening programs could be targeted. The study population will
comprise two cohorts, one prospective for subjects starting the study of pulmonary nodules
since site activation and onwards, and other retrospective for subjects who started the study
of pulmonary nodules from March 2019.